...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast cancer management. >Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow?
【24h】

Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow?

机译：针对乳腺癌中的BCL-2：利用肿瘤的生命线进行致命打击？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite their capacity for relentless growth, cancer cells are often poised in a life or death predicament. Faced with multiple genetic aberrations, tumors must recalibrate key survival pathways to sustain their growth: measures that also reduce their vulnerability to cytotoxic therapy. The steps taken to evade cell death are a recognized hallmark of cancer. Intense efforts over the last two decades have provided important insights into the molecular mechanisms that govern programmed cell death. Based on promising preclinical and early-phase studies in hematopoietic and other cancers, it now seems likely that novel targeted therapies against certain prosurvival pathways can be developed, thereby sensitizing cells to existing anticancer therapies . Indeed, evidence is emerging that a new class of drug, termed BH3 mimetics, may offer hope in targeting breast cancer.
机译：尽管癌细胞具有无休止的生长能力，但它们经常处于生死攸关的困境中。面对多种遗传畸变，肿瘤必须重新校准关键的生存途径以维持其生长：这些措施还可以降低其对细胞毒性疗法的脆弱性。规避细胞死亡的步骤是公认的癌症标志。在过去的二十年中，经过不懈的努力，对控制程序性细胞死亡的分子机制提供了重要见解。基于对造血和其他癌症的有希望的临床前和早期研究，现在似乎可以开发针对某些生存途径的新型靶向疗法，从而使细胞对现有的抗癌疗法敏感。实际上，越来越多的证据表明，一种称为BH3模拟物的新型药物可能为靶向乳腺癌提供希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号